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Abstract
Background: Human breast cancer is a heterogeneous disease consisting of multiple molecular subtypes.
Genetically engineered mouse models are a useful resource for studying mammary cancers in vivo under
genetically controlled and immune competent conditions. Identifying murine models with conserved human tumor
features will facilitate etiology determinations, highlight the effects of mutations on pathway activation, and should
improve preclinical drug testing.
Results: Transcriptomic profiles of 27 murine models of mammary carcinoma and normal mammary tissue were
determined using gene expression microarrays. Hierarchical clustering analysis identified 17 distinct murine
subtypes. Cross-species analyses using three independent human breast cancer datasets identified eight murine
classes that resemble specific human breast cancer subtypes. Multiple models were associated with human
basal-like tumors including TgC3(1)-Tag,T g W A P - Myc and Trp53
−/−. Interestingly, the TgWAPCre-Etv6 model mimicked
the HER2-enriched subtype, a group of human tumors without a murine counterpart in previous comparative studies.
Gene signature analysis identified hundreds of commonly expressed pathway signatures between linked mouse and
human subtypes, highlighting potentially common genetic drivers of tumorigenesis.
Conclusions: This study of murine models of breast carcinoma encompasses the largest comprehensive genomic
dataset to date to identify human-to-mouse disease subtype counterparts. Our approach illustrates the value of
comparisons between species to identify murine models that faithfully mimic the human condition and indicates that
multiple genetically engineered mouse models are needed to represent the diversity of human breast cancers.
The reported trans-species associations should guide model selection during preclinical study design to ensure
appropriate representatives of human disease subtypes are used.
Background
Breast cancer is the second leading cause of cancer-
related deaths in American women [1]. While increased
public awareness has led to earlier detection, a greater
understanding of tumor biology has led to the develop-
ment of many promising therapeutics [2,3]. A difficult
frontier, however, has been identifying the appropriate
target population for new drug(s) as not all breast cancer
patients will respond to a particular therapeutic. Cur-
rently, only approximately 5% of oncology drugs that enter
clinical testing are ultimately approved by the US Food
and Drug Administration for use [4]. This low success rate
reflects not only the difficulty of developing anticancer
therapeutics, but also identifies flaws in preclinical testing
methodology for selecting the most appropriate cancer
patient subset for early clinical testing [5,6].
Numerous murine models of breast cancer have been
created to mimic the genetic aberrations found in human
tumors [7-30]. Historically, each model has been analyzed
independent of other models, which complicates effective
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tiple models are consolidated into a single dataset, there is
increased sensitivity to detect features that are conserved
with the human disease state [31,32]. Identifying murine
models that faithfully mimic specific human breast cancer
subtypes [33-35] is an important need for the proper in-
terpretation of mouse model results, and thus for translat-
ing preclinical findings into effective human clinical trials
[36]. To address this need, we used a transcriptomic
approach to profile tumors from 27 different genetically
engineered mouse models (GEMMs). We define and
characterize 17 distinct murine subtypes of mammary car-
cinoma (referred to as classes herein to distinguish them
from the human subtypes), which we compare to three
human breast tumor datasets comprising over 1,700 pa-
tients to determine which GEMM classes resemble spe-
cific human breast cancer subtypes.
Results
Expression classes of genetically engineered mouse
models
As the genetic aberrations of human breast cancers have
been elucidated, murine models have been created to in-
vestigate the specific role that these genes/proteins have
on tumor phenotype. Since our initial comparative gen-
omics study of 14 mouse models and normal mammary
tissue [31], the number of breast cancer GEMMs in our
database has roughly doubled to 27 (Table 1). To com-
pare the transcriptomic diversity of these GEMMs, glo-
bal gene expression measurements from 356 unique
murine tumors and 16 normal murine mammary sam-
ples were analyzed using Agilent microarrays (Table 1A,
Figure 1; Table S1 in Additional file 1). Using this larger
and more diverse murine dataset, a new mouse ‘intrinsic
gene list’ was derived to identify genes associated with
all 27 models. As expected, many of the genes from the
previous intrinsic gene list were also present in the up-
dated list. After filtering for genes found in both data-
sets, 76.5% (500/654) of the intrinsic probes from
Herschkowitz et al. [31] were again included within the
new intrinsic list of 1,855 probes (Table S2 in Additional
file 1), which represents 1,841 genes.
To determine if new murine subtypes/classes exist in
this expanded dataset, SigClust analysis [37] was per-
formed using supervised hierarchical clustering of the
385 murine microarrays and the intrinsic 1,855 probe
list (Figure 2). Murine ‘classes’ were defined as having at
least five tumors with a SigClust P-value ≤0.01. Using
these criteria, 17 murine classes were identified with
94% (363/385) of tumors being included within one of
these classes (Figure 2B; Figure S1 in Additional file 2).
The name for each class was determined based upon the
major model contributor (for example, Myc
Ex), the
major biological feature (for example, Squamous-like
Ex),
or both (for example, p53null-Basal
Ex), with the super-
script ‘Ex’ designation used to denote that this is an
expression-based class. As previously observed [31], the
Brca1
+/− Trp53
+/− irradiated, TgC3(1)-Tag, TgMMTV-
Neu, TgWAP-Int3, TgWAP-Myc, and TgWAP-Tag mur-
ine models have ‘homogeneous’ gene expression patterns
in this dataset; here, a model was considered ‘homoge-
neous’ if ≥80% of tumors from that GEMM were found
within a single expression-defined class (Table 1B; Figure
S2 in Additional file 2). Many of the newest models also
showed homogeneous gene expression patterns, includ-
ing Stat1
−/−, TgMMTV-Myc, TgMMTV-Wnt1/iFGFR2,
and TgWAPCre-Etv6.
Other models showed a ‘semi-homogeneous’ gene ex-
pression pattern, defined as ≥80% of tumors from a sin-
gle GEMM being found within two classes. These
included Pik3ca-H1047R, TgMMTV-Atx, TgMMTV-Fgf3,
TgMMTV-Hras, TgWAP-T121,a n dT g M M T V - Wnt1.
Interestingly, while maintaining the TgMMTV-Wnt1
mouse colony, it was observed that there might be two
types of tumors based on latency, namely early and late
arising tumors. This observation was also reflected in the
two TgMMTV-Wnt1 expression classes that also differed
by median tumor latency: Wnt1-Early
Ex (8.8 weeks) and
Wnt1-Late
Ex (22.2 weeks) (Wilcoxon Rank Sum P-value
<0.001). Lastly, about 40% of mouse mammary tumor
virus (MMTV) driven Wnt1 tumors have cooperative
activation of fibroblast growth factor signaling [38], a
phenotype that is known to decrease tumor latency [16],
and consistent with this, 88% (7/8) of TgMMTV-Wnt1/
iFgfr2 tumors in our dataset were also classified as Wnt1-
Early
Ex.
The remaining models had ‘heterogeneous’ gene ex-
pression patterns, which were defined as no two classes
containing at least 80% of the tumors analyzed: Brg1
+/−
(five classes), DMBA-induced (five), p18
−/− (three), Rb1
−/−
(five), TgMMTV-Aib1 (four), TgMMTV-Cre Brca
Co/Co
Trp53
+/− (three), TgMMTV-Lpa (four), Trp53
−/− (seven),
and Trp53
+/− irradiated (four). Similar to recent reports
[32], the Trp53
−/− model (which is distinct from the
Trp53
+/− irradiated model) was primarily defined by three
murine classes in this analysis: p53null-luminal
Ex (27/58),
p53null-basal
Ex (15/58), and Claudin-low
Ex (7/58).
To begin investigating the defining features of these
classes, a comparison of selected cell lineage markers
was performed (Figure 2C). Several mouse classes highly
expressed luminal cell markers (for example, Erbb2,
Esr1, Krt18, and/or Krt19), including Erbb2-like
Ex, PyM-
T
Ex, Neu
Ex, Myc
Ex, and Stat1
Ex. Other classes expressed
basal cell cytokeratins (for example, Krt5, Krt14 and/or
Krt17), including Wnt1-Late
Ex, Wnt1-Early
Ex, p53null-
Basal
Ex, Squamous-like
Ex, Class14
Ex, and C3Tag
Ex.A s
identified previously [31], a murine Claudin-low
Ex class
was observed to be characterized by low expression of
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A. B.
Tumor model Strain Promoter Transgene Reference Primarily found in murine class(es): Intramodel
variation
Brg1
+/− Mixed Brg1 heterozygous [7] Squamous-like
Ex (4/12);
Erbb2-like
Ex (3/12); 3 others
Heterogeneous
Normal
mammary-lactating
FVB Normal lactating
mammary tissue
Normal-like
Ex (2/2) Homogeneous
p18
−/− BALB/c p18 homozygous null [8] Erbb2-like
Ex (5/9); Normal-like
Ex
(2/9); Squamous-like
Ex (1/9)
Heterogeneous
Pik3ca-H1047R FVB MMTV Pik3ca H1047R mutation
overexpression
[9] Class14
Ex (5/12); Squamous-like
Ex
(5/12); 2 others
Semi-homogeneous
Rb
−/− Mixed Rb homozygous null [10] Erbb2-like
Ex (4/10); Neu
Ex (1/10); 3 others Heterogeneous
Stat1
−/− C57BL/6J Stat1 homozygous null [11] Stat1
Ex (7/7) Homogeneous
TgMMTV-Aib1 FVB MMTV Aib1 overexpression [12] Erbb2-like
Ex (4/9); Myc
Ex (2/9); 2 others Heterogeneous
TgMMTV-Atx FVB MMTV Atx overexpression [13] Class14
Ex (3/5); Squamous-like
Ex (1/5); 1 other Semi-homogeneous
TgMMTV-Fgf3 FVB MMTV Fgf3 overexpression [14] Erbb2-like
Ex (2/5); Normal-like
Ex
(2/5); Wnt1-Late
Ex (1/5)
Semi-homogeneous
TgMMTV-Hras FVB MMTV Hras overexpression [15] Neu
Ex (5/8); Class8
Ex (2/8) Semi-homogeneous
TgMMTV-Lpa FVB MMTV Lpa1, Lpa2,o rLpa3
overexpression
[12] Normal-like
Ex (6/15);
Claudin-low
Ex (3/15); 3 others
Heterogeneous
TgMMTV-Myc FVB MMTV cMyc overexpression [15] Myc
Ex (4/5); Class8
Ex (1/5) Homogeneous
TgMMTV-Wnt1,iFgfr FVB MMTV Wnt1 overexpression,
inducible Fgfr1 or Fgfr2
[16] Wnt1-Early
Ex (7/12) Homogeneous
TgWAPCre-Etv6 Mixed WAP Etv6-Ntrk3 fusion gene
overexpression
[17] Erbb2-like
Ex (12/12) Homogeneous
Brca1
+/−, Trp53
+/−,
irradiated
BALB/c Brca1 and Trp53
heterozygous, irradiated
[18] p53null-Basal
Ex (6/7);
Wnt1-Early
Ex (1/7)
Homogeneous
DMBA-induced FVB DMBA treated [19] Squamous-like
Ex (4/11); Claudin-low
Ex
(3/11); 3 others
Heterogeneous
Normal mammary Mixed Normal mammary tissue Normal-like
Ex (16/16) Homogeneous
TgC3(1)-Tag FVB C3(1) SV40 large T antigen [20] C3Tag
Ex (28/30);
Claudin-low
Ex (2/30)
Homogeneous
TgMMTV-Cre
Brca1
Co/Co, Trp53
+/−
C57BL/6J MMTV Brca1 flox, Trp53
heterozygous
[21] p53null-Basal
Ex (4/10);
Claudin-low
Ex (3/10); 1 other
Heterogeneous
TgMMTV-Neu FVB MMTV Rat Her2 overexpression [22] Neu
Ex (25/28); Normal-like
Ex
(2/28); 1 other
Homogeneous
TgMMTV-PyMT FVB MMTV Py-MT overexpression [23] PyMT
Ex (9/17); Class3
Ex (1/17) Homogeneous
TgMMTV-Wnt1 FVB MMTV Wnt1 overexpression [24] Wnt1-Early
Ex (15/25);
Wnt1-Late
Ex (7/25); 3 others
Semi-homogeneous
TgWAP-Int3 FVB WAP Notch4 overexpression [25] WapINT3
Ex (6/7); Class3
Ex (1/7) Homogeneous
TgWAP-Myc FVB WAP cMyc overexpression [26] Myc
Ex (18/21); Class8
Ex (3/21) Homogeneous
TgWAP-T121 Mixed WAP pRb, p107, p130
inactivation
[27] Erbb2-like
Ex (3/6); Class3
Ex (2/6);
Claudin-low
Ex (1/6)
Semi-homogeneous
TgWAP-T121, Trp53
+/−
B6D2F1 WAP pRb, p107, p130
inactivation, Trp53het
[27] C3Tag
Ex (1/1)
TgWAP-Tag C57BL/6J WAP SV40 large T antigen [28] C3Tag
Ex (4/4) Homogeneous
Trp53
−/− BALB/c Trp53 homozygous null [29] p53null-Luminal
Ex (27/58);
p53null-Basal
Ex (15/58); 5 others
Heterogeneous
Trp53
+/−, irradiated BALB/c Trp53 heterozygous,
irradiated
[30] p53null-Basal
Ex (4/8); Claudin-low
Ex
(2/8); 2 others
Heterogeneous
A complete list of all GEMMs used. The bottom 15 models/normal mammary were studied by Herschkowitz et al. [31]. C3(1), 5' flanking region of the C3(1)
component of the rat prostate steroid binding protein. MMTV, mouse mammary tumor virus. WAP, whey acidic protein.
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and high expression of epithelial-to-mesenchymal transi-
tion genes (Snai1 and Zeb2), similar to the human claudin-
low subtype [34].
Comparison of murine class defining gene sets versus
human tumor subtypes
To specifically compare murine classes to human breast
cancer subtype features, each murine class defining sig-
nature (Figure 2i-v) was tested for differential expression
across the human subtypes using the UNC308 dataset
(Figure 3A-E) [34]. For example, the high expression
signature that defines the murine Claudin-low
Ex class
(Figure 2i; including Hic1, Il6st, Klf2, Maf, Pdgfra,
Prrx1, Snai1)w a sa l s ot h em o s th i g h l ye x p r e s s e di n
human claudin-low tumors (Figure 3A). Figure 2ii
shows genes that are highly expressed in the newly identi-
fied Stat1
Ex and Class14
Ex murine classes, which show lu-
minal characteristics (for example, Foxa1, Esrrb) and are
the most highly expressed in human luminal A tumors
(Figure 3B). While most of the GEMMs in this dataset are
considered estrogen receptor (ER) negative, murine
models comprising these two classes (Stat1
−/− and Pik3ca-
H1047R, respectively) were often ERα
+ [9,11], and these
data suggest that they overall have a ‘luminal’ expression
profile. Interestingly, these classes cluster independent of
the previously defined murine luminal models, TgMMTV-
Neu and TgMMTV-PyMT. Consistent with the individual
cell lineage marker analysis, the Wnt1-Late
Ex,W n t 1 -
Early
Ex, p53null-Basal
Ex, Squamous-like
Ex, and Class14
Ex
murine classes express a basal-like gene signature
(Figure 2iii). As in human tumors, a proliferation sig-
nature (Figure 2iv) further distinguishes these murine
classes, with highest expression in murine C3Tag
Ex
and human basal-like tumors, and lowest expression
in normal tissues from both species. This finding is
likely due to the loss of RB1 function in both human
basal-like [39,40] and TgC3(1)-Tag murine tumors
(due to T-antigen expression). Lastly, Figure 2v high-
lights a gene cluster that is highly expressed in sev-
eral murine classes, including Erbb2-like
Ex,P y M T
Ex,
and Neu
Ex; this signature was lower in normal mam-
mary tissue, but highly expressed in the two lactating
mammary samples (Figure 3E). Consistent with this
observation, many of the genes in this signature are
involved in alveolar function (for example, Abcg2,
Folr1,a n dLalba).
For the dual purpose of validating our new classifica-
tion system and for investigating the degree of diversity
in our expanded dataset, the murine classes defined here
were compared to those from Herschkowitz et al. [31]
(Figure S3 in Additional file 2). The majority of the
Herschkowitz et al. classes had one-to-one matching
counterparts to those described here; however, two pre-
vious groups (IX-WapTag and X-C3Tag) were combined
into a single class in our dataset (C3Tag
Ex). Importantly,
several of the 17 murine classes defined here were not
present within the 10 classes of Herschkowitz et al.
(Erbb2-like
Ex, Class3
Ex, Class8
Ex, and Stat1
Ex), almost all
of which were populated by GEMMs that were new to
this study.
Given the discovery of novel murine classes, it was of
great interest to determine the degree to which this ex-
panded murine dataset might better encompass the
molecular diversity of the human subtypes. To directly
compare tumors across species, this mouse and the pre-
viously published UNC308 human datasets were nor-
malized into a single expression dataset and hierarchical
clustered using a combined mouse and human [41] in-
trinsic gene list (Figure 4). While technical differences
between the two datasets (for example, different micro-
array platforms, different common references) may limit
Normalization Using
TgMMTV-Neu and TgC3(1)-Tag
Unsupervised Cluster to
Derive Intrinsic Gene List  Mouse Classes Using SigClust
 Intrinsic Gene Analysis to Define Class Based Supervised
Analysis Using SAM
3069 Genes 1841 Genes 899 Genes 4660 Genes
Human and Mouse
Comparison using GSA
22K
44K
180K
Calculate NF
Calculate NF
Normalized
Dataset
385 Microarrays
Apply NF
Apply NF
Figure 1 Flowchart of murine expression data analysis. Agilent microarrays from three different platforms were normalized and combined
together to create a single murine expression dataset. Next, an unsupervised cluster analysis using variably expressed genes was performed to
define a murine ‘intrinsic gene list’. Third, this intrinsic list was used as part of a supervised cluster analysis to objectively define murine subtypes/
classes. Fourth, class based supervised analyses were used to define murine class specific lists (genes and pathways). Finally, supervised
comparative analysis between human subtypes and mouse classes was used to identify and characterize human-mouse counterparts.
NF, normalization factor. GSA, gene set analysis; SAM, Significance Analysis of Microarrays.
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nodes were observed (Figure 4A). Interestingly, all major
nodes contained a combination of human and mouse sub-
types (Figure 4B), indicating a degree of similarity not only
between specific corresponding tumor subtypes, but
also globally across species. Most of the major intrin-
s i cg e n es e t sd r i v i n gt h en o d e sa r eh i g h l i g h t e db e l o w
the dendrogram, including the basal (Figure 4C), pro-
liferation (Figure 4D), normal breast (Figure 4E), claudin-
low subtype high expression (Figure 4F), and luminal
(Figure 4G) signatures. These clusters highlight the broad
conserved intrinsic features between mouse and human
tumors. For instance, most C3Tag
Ex tumors cluster with
the basal-like subtype, an association that is driven in part
(See figure on previous page.)
Figure 2 Murine intrinsic class analysis. (A) Supervised cluster using the newly derived murine intrinsic gene list and all murine arrays in the
dataset. Roman numerals next to the gray bars correspond to the enlarged regions in parts (i) to (v). (B) Dendrogram of the cluster from part (A)
with the murine classes identified by SigClust highlighted. Classes with colored boxes have been determined to be human expression-based
subtype counterparts. (C) Breast cancer genes and individual cell lineage marker expression profiles. (i) Claudin-low gene cluster. (ii) Luminal gene
cluster. (iii) Basal gene cluster. (iv) Proliferation gene cluster. (v) Lactating gene cluster.
Figure 3 Murine intrinsic cluster signatures according to tumor subtype. Standardized, average expression values for the dominant
individual gene clusters from Figure 2i-v are shown according to the murine classes (left panels) and the human subtypes (right panels) using
the human UNC308 human breast cancer dataset. (A) Murine claudin-low subtype defining gene set. (B) Murine luminal subtype gene set.
(C) Murine basal-like subtype gene set. (D) Murine proliferation-associated gene set. (E) Murine lactation associated gene set.
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which is known to contain many E2F-regualted genes.
To more objectively validate the trans-species associa-
tions observed in Figure 4, similarity between specific
human and mouse subtypes was measured using gene
set analysis (GSA) (Table 2) [42]. Using this approach, a
murine class was judged to be a strong human subtype
counterpart if the human-to-mouse comparison was sta-
tistically significant (P ≤ 0.05) in at least two of the three
human datasets analyzed (UNC308 [34], Combined855
[43], and TCGA547 [39]). As previously observed [31],
the murine Normal-like
Ex, C3Tag
Ex, and Claudin-low
Ex
classes associate with the human normal-like, basal-like,
and claudin-low subtypes, respectively. The new murine
class, Erbb2-like
Ex, was associated with the human
HER2-enriched subtype across all three human data sets;
this human breast cancer subtype did not associate with
any previously characterized murine class [31], indicat-
ing an increased ability for the current dataset to en-
compass more of the major human intrinsic subtypes.
With this larger sample size, a link was also identified
between the Myc
Ex class and human basal-like breast
cancer, which is consistent with multiple human studies
linking basal-like breast cancers with cMYC amplifica-
tion and expression signatures [39,44]. Interestingly, a
connection between the Myc
Ex class and human luminal
B tumors was also identified, highlighting Myc activation
as a potentially important etiological mechanism that is
shared between these two aggressive human subtypes.
Previously defined as a ‘luminal’ model [31], the Neu
Ex
murine class associated with the human luminal A sub-
type in this newest analysis; this correlation was some-
what surprising given the lack of ERα and ERα-regulated
gene expression in the murine Neu
Ex class, but does
suggest that human luminal A tumors have many ERα-
independent features. Although the murine p53null-
Basal
Ex versus human comparisons were not significant
after controlling for multiple comparisons, an almost
consistent significant association was seen with human
basal-like tumors (P-value=0.04, 0.05, and 0.06) in all
Figure 4 Human and murine intrinsic co-cluster. (A) Supervised cluster using a combined human and mouse intrinsic gene list and all murine
and UNC308 human arrays. Broad tumor clusters are highlighted with names corresponding to the major human subtype(s) found within each.
(B) Clustering location of all tumors as displayed by their human subtype or mouse class. (C) Basal gene cluster. (D) Proliferation gene cluster.
(E) Normal breast gene cluster. (F) Claudin-low subtype high expression gene cluster. (G) Luminal gene cluster.
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Human breast cancer subtype
Mouse
class
Basal-like Claudin-low HER2-enriched Luminal A Luminal B Normal-like Predicted human
counterpart P-value P-value P-value P-value P-value P-value
U C T UC T UC TUC T U C TU CT
WapINT3
Ex 0.06 0.09 0.17 - - NA - - - - 0.44 - 0.40 0.34 0.29 - - -
Erbb2-like
Ex 0.33 0.30 0.33 - - NA <1e-4* 0.01* 0.01* 0.31 - - 0.44 0.40 0.30 - - - HER2-enriched
Class3
Ex - - - 0.46 - NA 0.41 0.17 0.38 0.31 0.28 0.34 - - - 0.12 0.14 0.29
Myc
Ex 0.02* 0.01* 0.03* - - NA 0.22 0.11 0.07 - - - 0.06 0.01* 0.02* - - - Basal-like and Luminal B
PyMT
Ex 0.41 0.38 - - - NA 0.28 0.09 0.08 0.08 0.33 0.46 0.02 0.10 0.12 - - -
Neu
Ex - - - - - NA 0.44 0.36 0.42 <1e-4* 0.01* 0.02 0.10 0.36 0.43 - - - Luminal A
Normal-like
Ex - - - 0.14 0.21 NA - - - - 0.07 0.11 - - - <1e-4* 0.01* 5e-4* Normal-like
Class8
Ex - - - 0.09 0.06 NA 0.48 - - 0.40 0.46 0.11 - - - 0.28 0.25 0.26
Wnt1-Late
Ex 0.37 - - - - NA - - - 0.40 0.41 0.42 - 0.46 0.40 0.15 0.01* 0.21
Wnt1-Early
Ex 0.29 - - - - NA - - - 0.40 0.19 0.33 0.38 0.40 0.49 0.39 0.08 0.21
p53null-Basal
Ex 0.04 0.05 0.06 - - NA - - 0.16 - - - 0.48 0.29 0.20 - - - Basal-like
Squamous-like
Ex - - 0.35 0.11 0.02* NA 0.20 - - - - - - - - 0.18 0.09 0.10
Stat1
Ex - - - 0.37 0.32 NA 0.07 - - 0.31 0.30 0.16 - 0.48 0.41 0.38 0.39 -
Class14
Ex - - - 0.35 0.22 NA - - - 0.17 0.14 0.01* 0.45 - 0.11 0.06 <1e-4* 0.04* Normal-like
C3Tag
Ex 0.02* 0.02* 0.03* 0.38 - NA - - 0.24 - - - 0.28 0.12 0.02* - - - Basal-like
Claudin-low
Ex - - 0.38 5e-4* <1e-4* NA - - - - - 0.20 - - 0.41 - - 0.17 Claudin-low
p53null-Luminal
Ex 0.17 0.07 0.02* - - NA 0.35 0.23 0.15 - - - 0.24 0.24 0.16 - --
A comparative analysis of each murine class versus each human subtype. Statistically significant observations are highlighted with an asterisk (P< 0.05, false discovery rate <0.1). Comparisons without a P-value were
not found to have a positive association with each other. Abbreviation: U, UNC. C, Combined. T, TCGA. NA, not applicable.
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5three human datasets. Lastly, Class14
Ex tumors were iden-
tified as a counterpart for normal-like human tumors, and
of the 13 murine tumors comprising this class, 38% (5/13)
are from the Pik3ca-H1047R model. This class clusters in-
dependent of normal mammary tissue samples (which are
all classified as Normal-like
Ex), indicating that this associ-
ation is possibly not driven by contamination of normal
tissue in the tumor biopsies.
Conserved tumorigenic pathway signatures identified
between human-mouse counterparts
Many researchers have hypothesized that gene expres-
sion signatures may be a more robust means of utilizing
gene expression data for discovery and pathway-based
classification as they are composed of tens to hundreds
of coordinately expressed genes. To take advantage of
this approach, the median expression values for 963
publicly available pathway gene-signatures (Table S3 in
Additional file 1) were calculated separately for the
mouse and human datasets, and a two-class (class X
versus all others) Significance Analysis of Microarrays
(SAM) was used to identify pathways that were highly
expressed by each class/subtype with a false discovery
rate (FDR) of 0% (Tables S4-S26 in Additional file 1). To
visualize pathway similarities across species, gene signa-
tures highly expressed within each mouse class were first
grouped into ‘pathway meta-signatures’, similar to the
way coordinately expressed genes can be grouped into
‘gene signatures’. The average value of these ‘pathway
meta-signatures’ was then calculated for each human
tumor and displayed as standardized boxplots based on
their human breast cancer subtype for the eight mouse
classes with human counterparts (Figure 5). These box-
plots allow for broad trends to be observed between the
pathways highly expressed within each mouse class rela-
tive to human tumors, and in all instances, identified
tens of pathway signatures that were commonly
expressed across species. For instance, the average ex-
pression of the 135 pathway signatures highly expressed
in C3-Tag
Ex tumors were also very highly expressed in
human basal-like tumors (Figure 5, top left panel), con-
sistent with the gene level analysis. While these trends
are informative, it was of most importance to identify
the specific pathways that were highly expressed in both
mouse and their human counterparts; it is likely that
these shared pathways provide etiological insight and
highlight potentially important cancer driving pathways.
A subset of the pathways identified as highly expressed
in both human and mouse counterparts are displayed
below each graph, with all across-species conserved
pathways presented in Table S3 in Additional file 1.
Three murine classes overlapped with human basal-
like tumors (Figure 5). One common feature between
these human and mouse tumors included Trp53 loss/
mutation, which in human basal-like tumors occurs
in >85% of the samples [39]. This trait was most apparent
in C3-Tag
Ex and p53null-Basal
Ex murine tumors on both
the genetic and the expression level. The second cardinal
feature of human basal-like tumors is high proliferation,
primarily resulting from retinoblastoma protein loss
[39,40]. Consistent with this finding, all three basal-like
mouse classes highly expressed cell cycle and/or retino-
blastoma pathway-related signatures. In addition, C3Tag
Ex
tumors were enriched for KRAS amplicon genes, b-MYB
activation, mutant PIK3CA, and FAS signaling. Murine
Myc
Ex tumors were also enriched for b-MYB activation
and mutant PIK3CA signaling, in addition to a HER1-
pathway signature and E2F signaling. Lastly, the p53null-
Basal
Ex class was enriched for a SRC activation signature,
a HER1-pathway signature, and the KRAS amplicon. These
findings are relevant since it has been shown that human
basal-like tumors also highly express the b-MYB signature
[45], are often KRAS [46] and cMYC amplified [39],
and show a PIK3CA-activation signature [39,47]. Thus,
for human and murine basal-like cancers, both the under-
lying molecular genetics and their expression profiles are
very similar across species.
Human and mouse claudin-low tumors also share
many features, including high expression of immune cell
associated genes/signatures (for example, B cell receptor,
PD1, and T cell receptor signaling), which is likely due
to consistently infiltrating immune cells. Both human
HER2-enriched and murine Erbb2-like
Ex tumors highly
expressed the EIF2 pathway, GATA3 induced genes, and
p53 independent DNA damage response genes. Human
luminal A and murine Neu
Ex tumors exhibited high ex-
pression levels of several tyrosine kinase-associated path-
way signatures, including EGF, HER2, PDGF, TGFβ, and
PIK3CA signaling. In support of this EGF/HER2 path-
way finding, it was recently shown that TgMMTV-Neu
tumors therapeutically respond to lapatinib (a dual
EGFR and HER2 inhibitor) treatment [48], as would be
predicted by the nature of this transgene. In addition
to mimicking human basal-like tumors, the murine
Myc
Ex class was also a counterpart for the luminal B
subtype. Interestingly, many of the same pathways
that were common with basal-like tumors are also
shared with luminal B tumors, highlighting potentially
important etiological events that are shared between
these two aggressive intrinsic subtypes; these features
include proliferation/retinoblastoma related pathways,
increased chromosome instability, and altered DNA
damage repair mechanisms.
Discussion
Human breast cancer is a genetically complex disease
consisting of well characterized molecular subtypes
[33,35]. Mouse models can provide an excellent resource
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chosen models accurately replicate genetic alterations
and overall phenotypes observed in human tumors.
Thus, a number of considerations must be kept in mind
when designing and/or selecting GEMMs to mimic the
human disease state; these features should include intra-
model tumor diversity, the degree of genetic similarity,
the degree of transcriptomic similarity, and histological
similarity (a topic not addressed here). By consolidating
mouse models of breast carcinoma into a single dataset,
this study was able to investigate the first three of these
issues, in which we identified murine models for all of
the major human expression subtypes.
To address intramodel tumor diversity, three types
of models were identified based on hierarchical clus-
tering analysis: ‘homogeneous’, ‘semi-homogeneous’,a n d
‘heterogeneous’. ‘Homogeneous’ GEMMs were associated
with a single murine expression class and were generally
created through the expression of oncogenes, possibly
relying less on secondary or tertiary mutations that arise
during tumor progression. These GEMMs make good ex-
perimental models because the phenotypes of individual
tumors are consistent and similar. ‘Semi-homogeneous’
models, such as TgMMTV-Wnt1, were associated with
two murine classes. We hypothesize that unknown sec-
ondary events after the initial transgene lesion determine
the class fate of these developing tumors. These varying
combinations of secondary lesions may cooperate with ab-
errant Wnt1 signaling to target different mammary cell
populations, contributing to model complexity. The last
type of model comprises tumors with ‘heterogeneous’gene
expression patterns (that is, models showing three or
more distinct phenotypes). In contrast to ‘homogeneous’
models, the majority of the ‘heterogeneous’ models were
Figure 5 Conserved signaling pathways between human-mouse counterparts. A two-class SAM (class X versus all others) was used to iden-
tify pathways highly expressed in each murine class. Pathways highly expressed with a FDR of 0% were grouped together to define a ‘pathway
meta-signature’ for each murine class (with the total number of pathway signatures included shown on the left axis). The standardized, average
expression values of each ‘pathway meta-signature’ were calculated in the UNC308, Combined855, and TCGA547 human datasets, which are dis-
played as boxplots according to their intrinsic human subtype. A subset of the pathways independently identified to be highly expressed in both
human-mouse counterparts (as indicated by the asterisk) for all three human datasets is displayed below each plot.
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genes. Again, we hypothesize that secondary events after
the initial transgene lesion are involved in the class fate
determination of these tumors. For example, the Trp53
−/−
model shows specific DNA copy number changes associ-
ated with each expression class [32]. From an experimental
perspective, special considerations (that is, phenotyping
each individual tumor) must be made to account for this
heterogeneity, especially when these models will be utilized
for therapeutic efficacy testing.
Despite the diversity of the models tested here, we
found that these mouse models collapse into distinct
murine classes that recapitulate specific human subtypes
on a gene expression-based level. These results are im-
portant as they allow for the identification of shared
characteristics/lesions between murine and human tu-
mors, and they direct researchers toward appropriate
in vivo models of specific human subtypes for future ex-
perimental testing. Basal-like breast tumors are one the
most aggressive subtypes of breast cancer. Herein, we
find that three murine classes recapitulated human
basal-like breast cancers: C3Tag
Ex, Myc
Ex, and p53null-
Basal
Ex. The human basal-like subtype is characterized
by high proliferation [49], genomic instability [46], and
expression of a c-MYC signature [39,44]. These murine
classes share these hallmarks as evident by high expres-
sion of the proliferation gene cluster, cell cycle pathways,
and chromosome instability gene-signatures; thus, there
are clear GEMMs of human basal-like tumors that share
both common genetic drivers and expression features.
Murine Claudin-low
Ex tumors were identified that
significantly mimic the human claudin-low subtype;
however, no homogeneous murine model was specific
to this class/subtype. Instead, rare tumors from mul-
tiple heterogeneous models coalesced into the murine
claudin-low group. As an experimental solution to this
heterogeneous GEMM complication, the T11 orthotopic,
transplantable syngeneic model was derived from a
Claudin-low
Ex BALB/c Trp53
−/− tumor (753R), which
maintains its claudin-low expression features even after
multiple transplant passages [32]. This transplantable
model has been used for extensive therapeutic testing
[48], thus suggesting that one method of ‘capturing’ a
heterogeneous model in a single state can be accom-
plished via the serial transplantation of a phenotypically
characterized individual tumor. As in the human claudin-
low subtype, Trp53 mutation/loss was a common genetic
event in mouse Claudin-low
Ex tumors. Similarly, both spe-
cies highly express epithelial-to-mesenchymal transition
related genes and inflammatory gene signatures, and have
low expression of many epithelial cell adhesion genes, in-
cluding E-cadherin [34].
Discovered here was the Erbb2-like
Ex murine class,
which associated with human HER2-enriched tumors
even without highly expressing the Erbb2 gene; no mouse
model from our previous studies mimicked this aggressive
human tumor subtype. One homogeneous model was
found within this class, namely TgWAPCre-Etv6. This
model expresses the Etv6-Ntrk3 fusion gene product, a
protein that has been associated with secretory breast can-
cers [50]. Consistent with this, we observed that murine
Erbb2-like
Ex tumors highly express a gene signature in
common with lactating normal mammary tissue.
For the human luminal breast cancer subtypes, our
previous study identified that the TgMMTV-Neu model
represents the luminal subtypes more than it resembles
HER2-enriched tumors [31]. We provide further evi-
dence here that the murine Neu
Ex class specifically asso-
ciates with human luminal A tumors. Conserved with
humans, murine Neu
Ex tumors highly express several
tyrosine kinase pathway-related gene-signatures, namely
EGFR and HER2, which would be expected based upon
the nature of the Neu/ERBB2 transgene. It has been
shown that TgMMTV-Neu tumors regress with lapatinib
treatment [48], giving credence to our approach for
identifying drug targetable driver/maintenance pathways
in these tumors using a computational pathway-based
approach. Interestingly, only the murine Myc
Ex class was
shown to consistently associate with luminal B tumors.
Since the Myc
Ex class was also identified as a basal-like
model, aberrant Myc activation may be a common hall-
mark of these two aggressive subtypes.
While our main focus was to identify human-to-
mouse disease counterparts, about half of the mouse
classes did not statistically associate with specific human
subtypes by our broad analysis. Several of these mouse-
specific classes, however, had clear basal-like tumor ex-
pression features, including WapINT3
Ex, Wnt1-Late
Ex,
Wnt1-Early
Ex, and Squamous-like
Ex. Unlike the other
three, the Squamous-like
Ex class consisted of a variety of
models (for example, Pik3ca-H1047R, Brg1
+/−, and
DMBA-induced) and trended toward an association with
human claudin-low tumors. Similarly, several classes had
luminal expression features, highlighted by PyMT
Ex and
Stat1
Ex. Although the PyMT
Ex class had a relatively
small number of samples, these tumors trended toward
an association with the luminal B subtype. The Stat1
Ex
class also had several strong luminal features, consistent
with prior characterization of this model [11]. Given the
expression of ERα in these STAT1-defecient tumors [11],
the lack of an association with either the luminal A or
luminal B human subtypes was unexpected.
An unanswered question concerning these human-to-
mouse associations is the finding that murine classes like
Erbb2-like
Ex, and Neu
Ex, associate with specific human
subtypes despite the fact that they apparently do not
show expression of one of these human subtype-defining
genes (HER2/ERBB2 in the case of Erbb2-like
Ex and
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Ex). Three hypotheses that could
explain this finding are: 1) the cell type of origin of the
tumor (but not a genetic driver) is the same across
species and this is the major linking phenotype; 2)
additional unknown genetic driver(s) are responsible
for the common phenotype across species; or 3) some
combination of hypothesis 1 and 2. We favor the common
cell type of origin hypothesis, but additional experiments
like lineage tracing will be required to unequivocally de-
termine this.
Related to this, there are at least two confounding fea-
tures within our dataset that should also be considered
when interpreting these results. First, most of the
oncogene-driven mouse models analyzed here used either
the MMTV or WAP promoter in their design. If the activ-
ity of these promoters varies as a function of specific mam-
mary cell types, such as luminal versus myoepithelial cells,
then only those cells that naturally use these promoters
would ever give rise to a tumor in these models; we note
that most of the MMTV or WAP driven tumors were lu-
minal. Second, similar complications potentially exist with
regards to mouse strain. Varying the background genetics
in which a model is designed can influence tumor pheno-
type, and thus classification. Unfortunately, our dataset is
underpowered to adequately address these two confound-
ing features, but future experiments/models could be de-
signed to address these questions.
While some of the mouse classes were identified as
good counterparts for specific human subtypes, many
were not. There are several possibilities to explain this
lack of association. The first is that these classes are spe-
cific to murine mammary carcinomas and do not have a
matching counterpart in humans. The second might be
that these murine classes model rare phenotypes that
exist in only a small subset of human breast cancer pa-
tients, and that these rare human subtypes were not
present in the datasets used here. Similarly, more mouse
tumors for classes with small numbers may be required
to increase statistical power to detect an association; for
example, we hypothesize this to be the case for the PyM-
T
Ex class. The third possibility is that these novel murine
classes share phenotypes with multiple human subtypes,
and thus may never be classified as being similar to a
single human subtype. Some murine tumor features
were shared across multiple human subtypes (for ex-
ample, Myc
Ex with human basal-like and luminal B),
which our presented analysis is more likely to under-
value. While this study provides a framework for identify-
ing GEMMs that could be useful for preclinical drug
testing, the simultaneous analysis of 27 mouse models re-
stricted our trans-species comparisons to only expression-
based analyses. The scope of our future work will focus on
using models selected based upon these data for preclin-
ical therapeutic testing to better determine the
translational utility of these GEMMs. These experiments
are already underway and producing promising results
using the TgMMTV-Neu, TgC3(1)-Tag, and claudin-low
T11 models [48,51-53]. For example, in Roberts et al. [51],
we showed that the CyclinD1 dependent TgMMTV-Neu
tumors are sensitive to a CDK4/6 inhibitor, while the
basal-like TgC3(1)-Tag tumors were not; these studies are
consistent with findings coming from human clinical trials
of luminal/ER+breast cancers, which were generally
noted to be sensitive to a CDK4/6 inhibitor [54]. Similarly,
a trans-species genetic screen by Bennett et al. [53] identi-
fied two ribonucleotide reductase genes (RRM1 and
RRM2) and a checkpoint kinase (CHK1) as potential tar-
gets for triple-negative breast cancer patients, which they
validated in both species with drug treatment experiments
using TgC3(1)-Tag and human xenograft tumors.
Lastly, the data presented in this study may provide an
explanation for a recent paper that concluded that mur-
ine models are not helpful for studying acute human
inflammatory disease [55]. Their conclusion was drawn
from a comparison using a single mouse strain/model
(that is, C57BL6) versus a large number of humans.
Based on the data presented here, we predict that mul-
tiple mouse strains/models would need to be tested be-
fore such a conclusion could be made. To improve
preclinical study designs using mouse models for any dis-
ease, it is our recommendation that the following steps be
used as guidelines: 1) select/create multiple mouse models
for comparative analysis to humans; 2) classify the pheno-
type(s) of each model with a specific focus on the degree
of intramodel ‘heterogeneity’; and 3) objectively compare
each model to the human disease state to identify the pos-
sible trans-species counterparts. With this approach, it is
likely that some strains/models might be rejected as not
mimicking the human disease state, while others may, and
it is those that do that are the most valuable for preclinical
testing. We suggest that the use of this approach will in-
crease the predictive nature of preclinical studies in mice.
Conclusion
We consolidate 27 murine models of breast carcinoma
into the largest comprehensive genomic dataset to date,
and we provide a detailed characterization of each to
better understand how these GEMMs recapitulate phe-
notypes of the human subtypes. The data presented here
provide insight into the molecular pathways involved in
specific breast cancer subtypes and should serve as a
useful resource when designing preclinical studies and
interpreting their results.
Materials and methods
Gene expression microarrays
A murine tumor dataset of 385 DNA gene expression
microarrays from 27 GEMMs of mammary carcinoma
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Of these, 275 samples were obtained from multiple pre-
vious publications (Gene Expression Omnibus accession
numbers GSE3165, GSE8516, GSE9343, GSE14457,
GSE15263, GSE17916, and GSE27101). The other 110
microarray samples (GSE42640) represent newly ob-
tained tumor samples from multiple participating inves-
tigators using methods approved by international animal
husbandry guidelines. Total RNA was purified from 20
to 30 mg of mouse mammary tumor using Qiagen’s
(Valencia, CA USA) RNeasy Mini Kit following the man-
ufacture’s protocols. RNA quantity and quality were de-
termined using the Nanodrop spectrophotometer and
Agilent Bioanalyzer, respectively. Total RNA was reverse
transcribed and labeled with cyanine-5 (Cy5) dye for ex-
perimental samples and cyanine-3 (Cy3) dye for mouse
reference samples [31] using the Agilent Low RNA Input
Fluorescent Linear Amplification Kit. Equal quantities of
labeled mouse reference RNA and tumor RNA were co-
hybridized overnight to Agilent microarrays, washed,
scanned and signal intensities were determined.
All tumor samples were co-hybridized to one of three
Agilent Technology gene expression microarray types:
22 K, 4X44K, or 4X180K (Figure 1). Two ‘homogeneous
expression’ murine models [31], namely TgMMTV-Neu
and TgC3(I)-Tag, were analyzed on all three array types.
Therefore, we used both of these models to normalize
expression between microarray types [32]. Ten microar-
rays (five TgMMTV-Neu and five TgC3(I)-Tag) from
each array type were used for normalization (30 micro-
arrays total). All microarray data were independently ex-
tracted from the UNC Microarray Database for each
array type as log2 Cy5/Cy3 ratios, filtering for probes
with Lowess normalized intensity values greater than 10
in both channels and for probes with data on greater
than 70% of the microarrays [31,34]. Before normalization,
each data set was imputed (via the 10 nearest neighbor
gene values) and then reduced to the probes that were
present on all three array type datasets (11,690 probes,
11,167 genes). Using the 10 normalization arrays per 3
array platforms, the median expression value was calcu-
lated for each probe, on each array type, and a
normalization factor was applied independently to each
probe so the median was the same for each array type.
Probe expression values were ‘median centered’ to obtain
the final normalized dataset. A principle component ana-
lysis was performed to verify the normalization.
Murine intrinsic genes and subtypes
After removing technical replicates, the dataset was fil-
tered to probes with at least three observations with an
absolute log2 expression value >3 using Gene Cluster 3.0
[56], which included 908 probes (899 genes). Hierarch-
ical clustering was performed with this unsupervised
probe list using centroid linkage and was viewed with
Java Treeview v1.1.5r2 [57]. Potential ‘intrinsic groups’ of
murine samples were defined as any set of samples/
arrays within this hierarchical cluster that had a Pearson
correlation value of 0.65 or greater [31]. Using these de-
fined groups (42 total), an ‘intrinsic gene list’ of 1,855
probes (1,841 genes) was identified with Intrinsic Gene
Identifier v1.0 (Max Diehn/Stanford University) by using
a cutoff of one standard deviation below the mean in-
trinsic gene value [31] (Table S2 in Additional file 1).
To identify significant murine ‘intrinsic subtypes’, the
385 sample dataset was clustered again using the 1,855
intrinsic probe list and SigClust [37] was used to identify
groups of samples with a significant association to one
another (P <0.01) [32]. GEMM classes were defined as
having at least five tumors and a SigClust P-value ≤0.01,
yielding 17 classes. Class-specific probes/genes were de-
termined using a two class (class X versus all other sam-
ples) SAM analysis (v3.11) [34,58] (Tables S4 to S20 in
Additional file 1).
Human and mouse intrinsic gene co-cluster
Prior to combining the two datasets, probes correspond-
ing to orthologous gene IDs (as determined by the
Mouse Genome Informatics of the Jackson Laboratory)
were averaged for both the mouse and UNC308 human
datasets. Using only orthologous genes found in both
datasets (8,034 genes), each tumor and gene was stan-
dardized to have an average expression of zero and a
standard deviation of one (N(0,1)) separately for each
species. Then, the datasets were merged and each gene
was median centered to obtain the final, normalized
combined dataset. A merged intrinsic gene list was cre-
ated by combining the 1,841 mouse intrinsic genes de-
fined here and the 1,918 human intrinsic genes from
Parker et al. [41] (3,310 unique genes in the combined
gene set). An intrinsic gene set hierarchical co-cluster was
performed using centroid linkage in Gene Cluster 3.0.
Comparison of murine and human expression subtypes
To identify possible commonalities between mouse clas-
ses and the human intrinsic subtypes of breast cancer
[34,41], we used the GSA R package v1.03 [42] and R
v2.12.2. Human subtype-specific gene lists were derived
for each subtype with a two class (subtype X versus all
other samples) SAM analysis independently for all of the
unique primary tumor samples from Prat et al. [34] (re-
ferred to as the UNC308 dataset), from Harrell et al. [43]
(Combined855 dataset), and from TCGA 2012 (TCGA547
dataset) [39] (Tables S21 to S26 in Additional file 1).
Human subtype-specific genes were classified as being
highly expressed in the subtype of interest and having a
SAM FDR of 0%. Murine classes were then analyzed for
significant overlap with each dataset’s human subtype-
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defined as having P≤0.05 and FDR ≤0.1 to control for
multiple comparisons [42]. These same methods were
used to identify significant overlap between our 17 newly
derived murine classes and the 10 previously defined
GEMM classes from Herschkowitz et al. [31], noting that
all 122 arrays used for the Herschkowitz et al. study were
also present within the 385 sample dataset used here
(Figure S3 in Additional file 2).
Conserved pathway gene signatures
Only genes that were found in both the human and
murine datasets were considered for gene-signature ana-
lysis in order to eliminate the influence of genes found
in only one dataset. Prior to calculating gene-signature
values, the human and murine datasets were separately
collapsed by averaging rows corresponding to the same
gene symbol. Median expression values were calculated
for 963 publicly available pathway-based gene signatures
using methods described in Fan et al. [59,60] (Table S3
in Additional file 1). A two class SAM (class or subtype
X versus all other samples) was used to identify path-
way signatures enriched in murine and human classes/
subtypes, which were defined as being upregulated with a
FDR of 0% (Tables S4 to S26 in Additional file 1).
Additional files
Additional file 1: Tables S1 to S26. A table of contents is listed on
the first worksheet that describes the information presented in
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Additional file 2: Figures S1 to S3. Figure S1: enlarges the cluster
dendrogram from Figure 2B, showing the clustering location and
expression class for each individual tumor in the mouse dataset.
Figure S2: clustering location for tumors of a given model from Figure 2B.
Figure S3: gene set analysis results comparing the 10 murine classes from
Herschkowitz et al. [31] and the 17 murine classes defined here.
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